ABC Arbitrage SA Invests $2.59 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• ABC Arbitrage SA has invested approximately $2.59 million in Thermo Fisher Scientific, acquiring 5,205 shares during the first quarter.
• Thermo Fisher reported an earnings per share (EPS) of $5.36 for the last quarter, surpassing analysts' expectations of $5.22, and achieved a revenue of $10.86 billion.
• The company declared a quarterly dividend of $0.43, with a dividend yield of 0.4%, to be paid on October 15th, with a payout ratio of 9.95%.

ABC Arbitrage SA bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,205 shares of the medical research company's stock, valued at approximately $2,590,000.

Other institutional investors have also recently made changes to their positions in the company. Revolve Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Port Capital LLC boosted its position in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after buying an additional 22 shares during the period. Clark Capital Management Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after buying an additional 23 shares during the period. Monograph Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock worth $4,507,000 after acquiring an additional 23 shares in the last quarter. Finally, Intergy Private Wealth LLC boosted its holdings in Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after acquiring an additional 23 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $6.15 during mid-day trading on Thursday, reaching $455.09. 1,490,140 shares of the company's stock were exchanged, compared to its average volume of 3,299,804. The business's fifty day simple moving average is $425.62 and its 200-day simple moving average is $464.94. The stock has a market capitalization of $171.85 billion, a PE ratio of 26.32, a price-to-earnings-growth ratio of 2.40 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the firm posted $5.37 EPS. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Analyst Ratings Changes

Several brokerages have recently issued reports on TMO. Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Argus lowered their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $593.00.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer owned 115,174 shares in the company, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 18,400 shares of company stock worth $8,345,792. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.